1. Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension 
William B. White, MD, Robert A. Hauser, MD, MBA, Gerald J. Rowse, PhD, Adam Ziemann, MD, PhD, L. Arthur Hewitt, PhD 
American Journal of Cardiology 
Volume 119, Issue 7, Pages (April 2017)
DOI: /j.amjcard
Copyright © 2017 The Author(s) Terms and Conditions

2. Figure 1
Patient flow and study groupings for analyses. DB = double-blind; DBHD = dopamine β-hydroxylase deficiency; MSA = multiple system atrophy; NDAN = nondiabetic autonomic neuropathy; OL = open-label; PBO = placebo; PD = Parkinson disease.
American Journal of Cardiology  , DOI: ( /j.amjcard )
Copyright © 2017 The Author(s) Terms and Conditions

3. Figure 2
Exposure-adjusted CV adverse events rates† occurring in the study groups (A) and incidence of CV adverse events in patients with or without preexisting cardiac disorders in the 8- to 10-week DB study (B). DB = double-blind; OL = open-label. *Patient-years of exposure = number of patients × mean days of exposure ÷ 365 days/year. †Adverse event rates = number of events ÷ patient-years of exposure.
American Journal of Cardiology  , DOI: ( /j.amjcard )
Copyright © 2017 The Author(s) Terms and Conditions